Benitec Biopharma's gene therapy BB-301 improved swallowing ability in all four OPMD patients followed for at least one year in a Phase Ib/II trial. One patient showed continued improvement at two years. The company plans to meet with the FDA in mid-2026 to discuss a pivotal study.
GLP-1 weight loss drugs show increasing efficacy but raise concerns about excessive weight loss, side effects, and the rise of unregulated compounded versions sold online.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06395740 |
Aspiration Pneumonia in Cerebrovascular Stroke Patients Suffering From Bulbar Palsy |
COMPLETED | PHASE4 |
| NCT05455359 |
Gastrointestinal Dysmotility on Aspiration Risk |
RECRUITING | PHASE4 |
| NCT03962725 |
Avoiding Neuromuscular Blockers to Reduce Complications |
TERMINATED | PHASE4 |
